Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 885,900 shares, a decrease of 19.5% from the September 15th total of 1,100,000 shares. Based on an average daily trading volume, of 1,820,000 shares, the short-interest ratio is currently 0.5 days.
A number of research analysts recently weighed in on RGLS shares. HC Wainwright reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Tuesday, September 1st. Wedbush reiterated a “hold” rating and issued a $1.00 price target on shares of Regulus Therapeutics in a research note on Friday, July 24th. Finally, Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $1.08.
RGLS traded down $0.01 during trading on Friday, reaching $0.51. The stock had a trading volume of 426,979 shares, compared to its average volume of 1,161,791. The stock has a 50 day moving average of $0.53 and a two-hundred day moving average of $0.64. The firm has a market capitalization of $18.50 million, a price-to-earnings ratio of -0.52 and a beta of 2.00. Regulus Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.74.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.12). Regulus Therapeutics had a negative return on equity of 214.08% and a negative net margin of 351.32%. As a group, equities research analysts expect that Regulus Therapeutics will post -0.83 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Regulus Therapeutics stock. Virtu Financial LLC acquired a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 84,348 shares of the biopharmaceutical company’s stock, valued at approximately $57,000. Virtu Financial LLC owned 0.40% of Regulus Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 17.64% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Read More: Understanding Market Liquidity
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.